4-(N-METHYL) AMINOPIPERIDINE MYRICETIN DERIVATIVE CONTAINING DITHIOCARBAMATE, PREPARATION METHOD AND APPLICATION

Abstract

The invention discloses a 4-(N-methyl) aminopiperidine myricetin derivative containing dithiocarbamate, and its preparation method and application, whose structural general formula is shown as follows: wherein R is substituted phenyl and substituted aromatic heterocyclic group; n is the number of carbons in the carbon chain, which are 2, 3, 4 and 5 respectively; the substitute phenyl group is an alkyl group containing C1-6, alkoxy group containing C1-6, nitro group, halogen atom or hydrogen atom in ortho-, meta- and para- position on that benzene ring; the aromatic heterocyclic group is thienyl, furyl, pyrrolyl and pyridyl groups; the substituents on the substituted aromatic heterocycle are o-, m-, and p- containing C1-6 alkyl, C1-6 alkoxy, nitro, halogen, and hydrogen atoms. The invention has better inhibitory activity on cancer cells.

Claims

1. A 4-(N-methyl) aminopiperidine myricetin derivative containing dithiocarbamate, whose structural general formula is shown as follows: ##STR00007## Wherein R is substituted phenyl and substituted aromatic heterocyclic group; n is the number of carbon in the carbon chain and can be 2, 3, 4 or 5.

2. The dithiocarbamate-containing 4-(N-methyl) aminopiperidine myricetin derivative according to claim 1, wherein the substituted phenyl group is a C1-6 alkyl group, a C1-6 alkoxy group, a nitro group, a halogen atom or a hydrogen atom on the benzene ring.

3. The 4-(N-methyl) aminopiperidine myricetin derivative containing dithiocarbamate according to claim 1, wherein the aromatic heterocyclic group can be thienyl, furyl, pyrrolyl or pyridyl groups.

4. The dithiocarbamate-containing 4-(N-methyl) aminopiperidine myricetin derivative according to claim 1, wherein the substituents on the substituted aromatic heterocyclic group are o-,m-,and p-C1-6 alkyl groups, C1-6 alkoxy groups, nitro groups, halogen atoms, or hydrogen atoms.

5. The preparation method of the 4-(N-methyl) aminopiperidine myricetin derivative containing dithiocarbamate according to claim 1 comprises the following specific steps: (1) 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxymyricetin (intermediate a) is prepared from myricetin and methyl iodide with crystalline potassium carbonate as catalyst under acidic conditions. ##STR00008## (2) 3-bromo-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b) is prepared from intermediate a and dibromoalkanes with different chain lengths using potassium carbonate as catalyst and N,N- dimethylformamide (DMF) as solvent as follows: ##STR00009## (3) Using intermediate b and 4-(N-methyl)amino-N-Boc piperidine as raw materials, potassium carbonate as catalyst and acetonitrile as solvent, 3-(4-(N-methyl) amino-N-Boc piperidine)-5,7-dimethoxy-2-(3,4,5- trimethoxyphenyl)-4H-chromene-4-one (intermediate c) is prepared under reflux at 80°C with continuous stirring, as shown below. ##STR00010## (4) Using intermediate c as a raw material, Boc protecting group is removed by HCl to obtain hydrochloride (intermediate d) of 3-(4-(N-methyl) aminopiperidine)-5,7-dimethoxy- 2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one, as shown below: ##STR00011## (5) 4-(N-methyl) aminopiperidine myricetin derivative containing dithiocarbamate (target compound A) is prepared by using intermediate d, carbon disulfide and benzyl chloride as raw materials, potassium carbonate as the catalyst and acetonitrile as the solvent, as shown below. ##STR00012##

6. An application of 4-(N-methyl) aminopiperidine myricetin derivative containing dithiocarbamate is to prepare medical medicament for inhibiting cancer cells.

Description

DETAILED DESCRIPTION OF THE INVENTION

Embodiment 1

[0024] The preparation method of 4-chlorobenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4, 5-trimethoxyphenyl)-4H-chromene-3-yl)oxy)propyl)(methyl)amino)piperidine-1- dithiocarboxylic acid (target compound A1) comprises the following steps:

[0025] (1) Preparation of 3-hydroxy -3′, 4′, 5′, 5, 7-hentamethoxymyricetin (intermediate a):

[0026] 4.64g myricetin (10 mmol), 22.09 g K2CO3•1/2H2O (16 mmol) and 120 mLDMF are added into a 250 mL round-bottom flask in turn. after stirring for 0.5-1 h at room temperature, 7.50 mL iodomethane (120 mmol) is slowly added dropwise, stirring at room temperature for 48 h, and TLC followed the reaction (methanol: ethyl acetate = 1: 4, V/V). After the reaction is stopped, the precipitate is filtered, the filter residue is washed with dichloromethane, the filtrates are combined, diluted with 100 mL of water, extracted with dichloromethane for three times, the organic layers are combined, concentrated under reduced pressure, then the concentrate is dissolved in 30 mL of anhydrous ethanol, heated to reflux, after the solution is clarified, 16 mL of concentrated hydrochloric acid is added under reflux, then yellow solid is precipitated, the reaction is continued for 2 hours, cooled, and filtered to obtain the crude product 3-hydroxy -3′,4′,5′,5,7-pentamethoxy myricetin (intermediate a), yield: 54.4%.

[0027] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)- 4H-chromene-4-one (intermediate b): 1.17 g (3 mmol)-3-hydroxy-3′,4′,5′,5,7-pentamethoxy myricetin (intermediate a), 1.66 g K2CO3 (12 mmol) and 30 mL DMF are sequentially added into a 100 mL single-necked round bottom flask and stirred at room temperature for 0.5-1 h, then 2.42 g 1,3-dibromopropane (12 mmol) is added, and the reaction is stirred at room temperature for 12 h. TLC is used to monitor the reaction (ethyl acetate). After the reaction is completed, the reaction solution is dispersed with 50 mL of water, and white solid is separated out. Suction filtration is carried out. then the solid is added to a round bottom flask containing 30 mL of solution (ethyl acetate: n-hexane = 3: 1) and stirred at room temperature for 4-5 h, suction filtration is carried out, and vacuum column chromatography is carried out for separation and purification (petroleum ether: ethyl acetate = 2: 1, V/V) to obtain white solid (intermediate b), with a yield of 78.9%.

[0028] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c):

[0029] 0.38 g (1.78 mmol) 4-(N-methyl)amino-N-Boc piperidine, 0.5 g (3.57 mol) K2CO3 and 40 mL acetonitrile are added into a 100 mL single-necked round-bottom flask, after the reaction mixture is stirred at room temperature for 0.5-1 h, 1 g(1.96 mmol) 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b) is added, then the reaction temperature is raised up to 80°C, and stirring at this temperature for 4-6 h. The reaction is monitored by TLC, when the reaction is finished, it is then cooled to room temperature, filtered to remove potassium carbonate and solid impurities, and the solvent is removed under reduced pressure to obtain a crude product (intermediate c) in the form of a burgundy oil for later use with yield:

[0030] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one:

[0031] In step (3), 4-((3-(5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chroman-3-yl)oxy)propyl)(methyl)aminotert-butyl)piperidine-1-carboxylic acid tert-butyl ester (intermediate c) is dissolved in about 30 mL methanol in a 100 mL single-necked round bottom flask , then 10 mL of 6 mol/L methanol hydrochloride solution is added, and stirred at room temperature for about 2 h. TLC followed the reaction. When the reaction is finished, the solvent is removed under reduced pressure, and a small amount of methanol is added to dissolve it. Then 20 mL of ethyl acetate is added. The mixture is continuously stirred until a yellow solid is separated out. The mixture is filtered, washed with ethyl acetate and dichloromethane respectively, and naturally dried to obtain a yellow solid (intermediate d), with a yield of 93.2%.

[0032] (5) Preparation of 4-chlorobenzyl-4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl) -4H-chromene-3-yl)oxy)propyl)(methyl)amino)piperidine-1-dithiocarboxylic acid (target compound A1):

[0033] 0.5 g (0.92 mmol) of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one, 0.25 g (1.84 mmol) of K2CO3 and 20 mL of acetonitrile are added to a 50 mL single-necked round bottom flask. After stirring for 1 h at room temperature, 0.7 g (9.21 mmol) of carbon disulfide is added dropwise under the ice bath. After stirring for 20 minutes, 0.15 g (0.92 mmol) of p-chlorobenzyl chloride is slowly added, then the reaction mixture is stirred for 2 h in ice bath. TLC followed the reaction and stopped the reaction when it is over. Poured the mixture into 100 mL of ice water, extracted with dichloromethane (3×20 mL), combined the organic layers, washed with saturated saline (3x20 mL), dried with anhydrous sodium sulfate, removed the solvent under reduced pressure to obtain the crude product, and purified by column chromatography (ethyl acetate: methanol = 5: 1 ∼ 1: 5, V/V) to obtain the target compound A1 with a yield of 74.7%.

Embodiment 2

[0034] The preparation method of 2-chlorobenzyl-4-((3-((5,7-dimethoxy-4-oxo-2- (3,4,5-trimethoxyphenyl)-4H-chromene-3-yl)oxy)propyl)(methyl)amino)piperidine-1- dithiocarboxylic acid (target compound A2) is as follows: [0035] (1) Preparation of 3-hydroxy-3′,4′, 5′,5,7-pentamethoxymyricetin (intermediate a): As in step (1) of Embodiment 1. [0036] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 1. [0037] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) propyl) (methyl)aminotert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0038] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromene -4-one: As in step (4) of Embodiment 1. [0039] (5) Preparation of 2-chlorobenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl) -4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A2): As in step (5) of Embodiment 1, the difference is that o-chlorobenzyl chloride is used as the raw material, and the yield is 75.1%.

Embodiment 3

[0040] The preparation method of 2,4-dichlorobenzyl 4-((3-((5, 7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A3) is as follows: [0041] (1) Preparation of 3-hydroxy-3′,4′,5′,5,7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0042] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene -4-one (intermediate b): As in step (2) of Embodiment 1. [0043] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran -3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0044] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0045] (5) Preparation of 2,4-dichlorobenzyl-4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A3): As in step (5) of Embodiment 1, the difference is that 2,4- dichlorobenzyl chloride is used as the raw material, and the yield is 80.3%.

Embodiment 4

[0046] The preparation method of 2-fluorobenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl)oxy)propyl)(methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A4) is as follows: [0047] (1) Preparation of 3-hydroxy-3′, 4′,5′,5,7-Pentamethoxymyricetin (intermediate a): As in step (1) of Embodiment 1; [0048] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl) -4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 1. [0049] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0050] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0051] (5) Preparation of 2-fluorobenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A4): As in step (5) of Embodiment 1, the difference is that o-fluorobenzyl chloride is used as the raw material, and the yield is 76.9%.

Embodiment 5

[0052] The preparation method of 3-methylbenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A5) is as follows: [0053] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5,7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0054] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl) -4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 1. [0055] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran -3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0056] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0057] (5) Preparation of 3-methylbenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl) -4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A5): As in step (5) of Embodiment 1, the difference is that m-methyl benzyl chloride is used as the raw material, and the yield is 65.3%.

Embodiment 6

[0058] The preparation method of 2-methylbenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A6) is as follows: [0059] (1) Preparation of 3-hydroxy -3′, 4′, 5′, 5,7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0060] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 1. [0061] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0062] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0063] (5) Preparation of 2-methylbenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl) -4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A6): As in step (5) of Embodiment 1, the difference is that o-methyl benzyl chloride is used as the raw material, and the yield is 44.4%.

Embodiment 7

[0064] The preparation method of 4-nitrobenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A7) is as follows: [0065] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5,7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0066] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene -4-one (intermediate b): As in step (2) of Embodiment 1. [0067] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0068] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0069] (5) Preparation of 4-nitrobenzyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl) -4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A7): As in step (5) of Embodiment 1, the difference is that p-nitrobenzyl chloride is used as the raw material, and the yield is 94.6%.

Embodiment 8

[0070] The preparation method of pyridine-3-ylmethyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A8) is as follows: [0071] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0072] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 1. [0073] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0074] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0075] (5) Preparation of pyridine-3-ylmethyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-chromene-3-yl) oxy) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A8): [0076] As in step (5) of Embodiment 1, the difference is that 3-(chloromethyl) pyridine is used as the raw material, and the yield is 65.2%.

Embodiment 9

[0077] The preparation method of (6-chloropyridine-3-yl) methyl 4-((3-((5,7-dimethoxy-4-oxo -2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxygen) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A9) is as follows: [0078] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a) As in step (1) of Embodiment 1. [0079] (2) Preparation of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene -4-one (intermediate b): As in step (2) of Embodiment 1. [0080] (3) Preparation of 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) propyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0081] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(3-(methyl (piperidin-4-yl) amino) propoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0082] (5) Preparation of (6-chloropyridine-3-yl) methyl 4-((3-((5,7-dimethoxy-4-oxo-2-(3,4, 5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxygen) propyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A9): [0083] As in step (5) of Embodiment 1, the difference is that 2-chloro-5-(chloromethyl) pyridine is used as the raw material, and the yield is 53.0%.

Embodiment 10

[0084] The preparation method of 4-chlorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A10) is as follows: [0085] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0086] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 1. The difference is that 1,4-dibromobutane is used as a raw material. [0087] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0088] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0089] (5) Preparation of 4-chlorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A10): As in step (5) of Embodiment 1, the yield is 34.3%.

Embodiment 11

[0090] The preparation method of 2-chlorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A11) is as follows: [0091] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5,7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0092] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 10. [0093] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0094] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0095] (5) Preparation of 2-chlorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A11): As in step (5) of Embodiment 2, the yield is 28.6%.

Embodiment 12

[0096] The preparation method of 2,4-dichlorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A12) is as follows: [0097] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a) As in step (1) of Embodiment 1. [0098] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 10. [0099] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0100] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0101] (5) Preparation of 2,4-dichlorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A12): As in step (5) of Embodiment 3, the yield is 31.3%.

Embodiment 13

[0102] The preparation method of 2-fluorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A13) is as follows: [0103] (1) Preparation of 3-hydroxy -3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0104] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 10. [0105] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0106] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0107] (5) Preparation of 2-fluorobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A13): As in step (5) of Embodiment 4, the yield is 39.9%.

Embodiment 14

[0108] The preparation method of 3-methylbenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A14) is as follows: [0109] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0110] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 10. [0111] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate C): As in step (3) of Embodiment 1. [0112] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0113] (5) Preparation of 3-methylbenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A14): As in step (5) of Embodiment 5, the yield is 48.4%.

Embodiment 15

[0114] The preparation method of 2-methylbenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A15) is as follows: [0115] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0116] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b). As in step (2) of Embodiment 10. [0117] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0118] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0119] (5) Preparation of 2-methylbenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A15): As in step (5) of Embodiment 6, the yield is 57.7%.

Embodiment 16

[0120] The preparation method of 4-nitrobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A16) is as follows: [0121] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0122] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 10. [0123] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0124] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0125] (5) Preparation of 4-nitrobenzyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl) -4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A16): As in step (5) of Embodiment 7, the yield is 47.6%.

Embodiment 17

[0126] The preparation method of pyridine-3-ylmethyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A17) is as follows: [0127] (1) Preparation of 3-hydroxy-3′,4′,5′,5 ,7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0128] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 10. [0129] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0130] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3, 4, 5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0131] (5) Preparation of pyridine-3-ylmethyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A19): As in step (5) of Embodiment 8, the yield is 50.5%.

Embodiment 18

[0132] The preparation method of (6-chloropyridine-3-yl) methyl-4-((4-((5,7-dimethoxy-4-oxo -2-(3, 4, 5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A18) is as follows: [0133] (1) Preparation of 3-hydroxy-3′, 4′, 5′, 5, 7-pentamethoxy myricetin (intermediate a): As in step (1) of Embodiment 1. [0134] (2) Preparation of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one (intermediate b): As in step (2) of Embodiment 10. [0135] (3) Preparation of 4-(4-((5,7-dimethoxy-4-oxo-2-(3,4,5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino tert-butyl) piperidine-1-carboxylic acid tert-butyl ester (intermediate c): As in step (3) of Embodiment 1. [0136] (4) Preparation of hydrochloride (intermediate d) of 5,7-dimethoxy-3-(4-(methyl (piperidin-4-yl) amino) butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromene-4-one: As in step (4) of Embodiment 1. [0137] (5) Preparation of (6-chloropyridine-3-yl) methyl-4-((4-((5,7-dimethoxy-4-oxo-2-(3,4, 5-trimethoxyphenyl)-4H-benzopyran-3-yl) oxy) butyl) (methyl) amino) piperidine-1-dithiocarboxylic acid (target compound A20): As in step (5) of Embodiment 9, the yield is 38.1%.

[0138] The physical and chemical properties and mass spectrum data of the synthesized dithiocarbamate-containing 4-(N-methyl) aminopiperidine myricetin derivative are shown in Table 1, and the nuclear magnetic resonance hydrogen spectrum (1H NMR) and carbon spectrum (13C NMR) data are shown in Table 2.

TABLE-US-00001 Physical and Chemical Properties of Compound A Prepared in Embodiments 1-18 Compound n R- group Mass Spectrometry Data , m/z (calcd) Character Melting Point/.sup.-C Yield% A.sub.1 3 4- Chlorobenzyl 743.22211 (743.22221[M+N].sup.+) Yellow Solid 117.4-118.4 74.7 A.sub.2 3 2- Chlorobenzyl 743.22028 (743.22221[M+N].sup.+) White Solid 133.5-133.9 75.1 A.sub.3 3 2,4- Dichlorobenzyl 777.18158 (777.18324[M+N].sup.+) White Solid 146.5-147.2 80.3 A.sub.4 3 2- Fluorobenzyl 727.25000 (727.25176[M+N].sup.+) White Solid 84.6-85.7 76.9 A.sub.5 3 3- Methylbenzyl 723.27478 (723.27683[M+N].sup.+) Yellow Solid 106.8-107.2 65.3 A.sub.6 3 2- Methybenzyl 723.27543 (723.27683[M+N].sup.+) Yellow Solid 97.7-98.1 44.4 A.sub.7 3 4- Nitrobenzyl 754.24445 (754.24626[M+N].sup.+) Grey Solid 141.2-142.9 94.6 A.sub.8 3 Pyridine -3- Ylmethyl 710.25648 (710.25643[M+N].sup.+) Yellow Solid 107.4-107.9 65.2 A.sub.9 3 (6- Chlorophyridine -3-yl) Methyl 744.21564 (744.21746[M+N].sup.+) Yellow Solid 93.2-93.8 53.0 A.sub.10 4 4- Chlorobenzyl 757.23700 (757.23786[M+N].sup.+) White Solid 116.9-117.2- 34.3 A.sub.11 4 2- Chlorobenzyl 757.23590 (757.23786(M+N].sup.+) Yellow Solid 96.9-97.4 28.6 A.sub.12 4 2,4- Dichlorobenzyl 791.19714 (791.19889[M+N].sup.+) Yellow Solid 101.7-102.1 31.3 A.sub.13 4 2- Fluorobenzyl 741.26563 (741.26741[M+N].sup.+) Yellow Oily - 39.9 A.sub.14 4 3- Methylbenzyl 737.29053 (737.29248[M+N].sup.+) Yellow Oily - 48.4 A.sub.15 4 2- Methylbenzyl 737.29010 (737.29248[M+N].sup.+) Yellow Oily - 57.7 A.sub.16 4 4- Nitrobenzyl 768.26050 (768.26191[M+N].sup.+) Red Oil - 47.6 A.sub.17 4 Pyridine -3- Ylmethyl 724.27008 (724.27208[M+N].sup.+) Red Oil - 50.5 A.sub.18 4 (6- Chloropyridine -3-yl) Methyl 758.23053 (758.23311[M+N].sup.+) Red Oil - 38.1

TABLE-US-00002 nuclear magnetic resonance spectrum data of compound A prepared in Embodiments 1-18 Compound .sup.1H NMR, .sup.13C NMR (TMS as internal standard) A.sub.1 .sup.1H NMR (400 MHz,DMSO) δ7.41 (d, J=8.5 Hz, 2H, Ph-H), 7.36 (t,J=4.2Hz, 4H, Ph-H), 6.83 (d,J =2.1 Hz, 1H, Ph-H), 6.49 (d, J= 2.0 Hz, 1H, Ph-H). 5.32 - 5.21 (m, 1H, Piperidinyl-H), 4.52 (d, J = 5.7 Hz, 2H, -S-CH.sub.2-) 4.47 - 4.36 (m, 1H, Piperidinyl-H),3.98 (t, J=6.1 Hz, 2H,-O-CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.2), 3.87 (s, 6H, Ph-OCH.sub.2),3.84 (s, 3H, Ph-OCH.sub.2), 3.75 (s, 3H, Ph-OCH.sub.2), 3.20 (dt, J = 40.6, 11.1 Hz, 2H, Piperidinyl-H),2.65-2.55 (m, 1H, Piperidinyl-H). 2.42 (s, 2H,-O-CH.sub.2CH-CH.sub.2-N-), 2.07 (s, 3H, N-CH.sub.3), 1.72 (dd, J = 18.5, 11.1 Hz, 4H, -O-CH.sub.2CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.36 - 1.22 (m, 2H, Piperidinyl-H) .sup.13C NMR (101 MHz, DMSO) δ 193.83, 172.68, 164.20, 160.76, 158.63, 153.15, 152.01, 140.47, 139.85, 136.26, 132.35, 131.45, 128.83, 126.14, 108.95, 106.33, 96.38, 93.56, 70.74, 60.68, 59.88, 56.57, 56.51, 51.20, 50.64, 49.39, 37.34, 28.54, 27.67. A.sub.2 .sup.1H NMR (400 MHz, DMSO) δ 7.61-7.56 (m, HI, Ph-H), 7.49 - 7.45 (m, 1H, Ph-H), 7.36 (s, 2H, Ph-H), 7.34 - 7.29 (m, 2H, Ph-H), 6.83 (d, J = 2.0 Hz, 1H, Ph-H), 6.49 (d, J=2.1 Hz, 1H, Ph-H), 5.32 - 5.20 (m, 1H, Piperidinyl-H), 4.59 (d, J = 7.6 Hz, 2H, -S-CH.sub.2-), 4.45 - 4.35 (m, 1H, Piperidinyl-H), 3.98 (t, J = 6.1 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3, 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.20 (dt, J =41.7, 11.1 Hz, 2H, Piperidinyl-H), 2.63 - 2.54 (m, 1H, Piperidinyl-H), 2.41 (t, J= 7.0 Hz, 2H, CH.sub.2, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.06 (s, 3H, N-CH.sub.3), 1.77-1.65 (m,4H, -O-CH-CH.sub.2CH.sub.2-N-, Piperidinyl-H, 1.39- 1.26 (m, 2H, Piperidinyl-H), .sup.13C NMR (101 MHz, DMSO) δ 193.56, 172.67, 164.19, 160.75, 158.63, 153.15, 151.99, 140.48, 139.83, 134.20, 133.93, 132.07, 129.97, 129.90, 127.85, 126.15, 108.95, 106.32, 96.38, 93.55, 70.74, 60.68, 59.84, 56.56, 51.10, 50.58, 49.44, 37.34, 28.55, 28.04.27.68. A.sub.3 .sup.1H NMR (400 MHz, DMSO) δ 7.64 (d, J= 2.0 Hz, 1H, Ph-H), 7.61 (d, J= 8.3 Hz, 1H, Ph-H), 7.40 (dd, J = 8.3,2.0 Hz, III, Ph-H), 7.37 (s, 2H, Ph-H), 6.83 (d, J = 1.8 Hz, 1H, Ph-H), 6.49 (d, J = 1.9 Hz, 1H, Ph-H), 5.24 (d, J = 10.4 Hz, 1H, Piperidinyl-H), 4.58 (d, J= 7.6 Hz, 2H, -S-CH.sub.2-), 4.41 (d, J = 11.6 Hz, 1H, Piperidinyl-H), 3.98 (t, J = 6.0 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.20 (dt, J = 22.1, 11.6 Hz, 2H, Piperidinyl-H), 2.57 (d, J = 9.9 Hz, 1H, Piperidinyl-H), 2.41 (t, J = 6.4 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.06 (s, 3H, N-CH.sub.3), L72 (dd, J = 18.5, 11.1 Hz, 4H, -O-CH.sub.2CH.sub.2CH.sub.3-N-, Piperidinyl-H), 1.32 (s, 2H, Piperidinyl-H). .sup.13C NMR (101 MHz, DMSO) δ 193.20, 172.67, 164.19, 160.73, 158.63, 153.14, 151.99,140.47,139.79,134.87, 133.67, 133.51, 133.16, 129.35, 127.96, 126.14, 108.92, 106.27, 96.37, 93.54, 70.73, 60.68, 59.83, 56.55, 56.51, 50.57, 38.72, 37.34, 36.25, 31.23, 28.54. A.sub.2 .sup.1H NMR (400 Mhz, DMSO) δ 7.51 (td, J = 7.7, 1.6 Hz, 1H, Ph-H), 7.38 - 7.31 (m, 3H, Ph-H), 7.23 -7.14 (m, 2H, Ph-H), 6.83 (d, J = 2.1 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.26 (d, J = 10.8 Hz, 1H, Piperidinyl-H), 4.51 (d, J = 5.6 Hz, 2H, -S-CH.sub.2-), 4.41 (d, J = 12.5 Hz, 1H, Piperidinyl-H), 3.98 (t, J = 6.1 Hz, 2H, -O-CH.sub.3CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.28 - 3.09 (m, 2H, Piperidintl-H), 2.57 (d, J = 11.0 Hz, 1H, Piperidinyl-H), 2.41 (t, J = 6.8 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.06 (s, 3H, N-CH.sub.3), 1.76 - 1.65 (m, 4H, -O-CH.sub.3CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.38 - 1.25 (m, 2H, Piperidinyl-H), .sup.13C NMR (101 MHz, DMSO) δ 193.51, 172.68, 164.19, 160.74, 159,70, 158.63, 153.14, 152.00, 140.47, 139.80, 132.02, 131.98, 130.27, 130.18, 126.14, 124.99, 124.96, 123.61, 123.46, 115.94, 115.73, 108.93, 103.28, 96.38, 93.54, 70.73, 60.67, 59.85, 56.55, 56.50, 50.58, 49.46, 37.32, 34.93, 28.54, 27.63, .sup.19F NMR (376 MHz, DMSO) δ -116.89; A.sub.5 .sup.1H NMR (400 MHz, DMSO) δ 7.36 (s, 2H, Ph-H), 7.23 - 7.15 (m, 3H, Ph-H), 7,07 (d, J = 6.8 Hz, 1H, Ph-H), 6.83 (d, J = 1.9 Hz, 1H, Ph-H), 6.49 (d, J = 2.1 Hz, 1H, Ph-H), 5.28 (d, J = 9.9 Hz, 1H, Piperidinyl-H), 4.44 (t, J = 9.1 Hz, 3H, -S-CH.sub.2-, Piperidinyl-H), 3.98 (t, J = 6.1 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.3-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.18 (dt, J = 40.8, 11.0 Hz, 2H, Piperidinyl-H), 2.59 (t, J = 11.0 Hz, 1H, Piperidinyl-H), 2.41 (t, J = 6.7 Hz, 2H,-O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.27 (s, 3H, Ph-CH.sub.3), 2.06 (s, 3H, N-CH.sub.3), 1.78 - 1.63 (m, 4H, -O-CH.sub.2CH.sub.3CH.sub.3-N-, Piperidinyl-H), 1.33 (s, 2H, Piperidinyl-H), .sup.13C NMR (101 MHz, DMSO) δ 194.18, 172.68, 164.19, 160.75, 158.63, 153.14, 152.00, 140.48, 139.82, 138.10, 136.47, 130.24, 128.85, 128.48, 126.78, 126.14, 108.94, 106.30, 96.37, 93.55, 70.74, 60.68, 59.90, 56.56, 56.50, 50.58, 49.36, 41.63, 37.33, 28.56, 27.69, 21.38. A.sub.6 .sup.1H NMR (4(x) MHz, DMSO) δ 7.36 (s, 2H, Ph-H), 7.26 (d, J = 8.0 Hz, 2H, Ph-H), 7.11 (d, J = 7.9 Hz, 2H, Ph-H), 6.83 (d, J = 2.1 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.28 (d, J = 9.9 Hz, 1H, Piperidinyl-H), 4.43 (dd, J = 14.4, 3.7 Hz, 3H, -S-CH.sub.2-, Piperidinyl-H), 3.98 (t, J = 6.1 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.3-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.26 - 3.08 (m, 2H, Piperidinyl-H), 2.58 (t, J = 11.0 Hz, 1H, Piperidinyl-H), 2.41 (t, J = 7.0 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-),2.27 (s, 3H, Ph-CH.sub.3), 2.06 (s, 3H, N-CH.sub.3), 1.78 - 1.63 (m, 4H, -O-CH.sub.2CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.33 (dd, J=34.5, 15.1 Hz, 2H, Piperidinyl-H). .sup.12C NMR (101 MHz, DMSO) δ 194.22, 172.67, 164.19, 160.74, 158.63, 153.14, 151.99, 140.48, 139.80, 137.05, 133.48, 129.60, 129.49, 126.15, 108.93, 106.28, 96.38, 93.54, 70.74, 60.68, 59.90, 56.55, 56.51, 50.57, 49.30, 41.40, 37.33, 28.56, 27.66, 21.16. A.sub.7 .sup.1H NMR (400 MHz, DMSO) δ 8.17 (d, J = 8.8 Hz, 2H, Ph-H), 7.66 (d, J = 8.7 Hz, 2H, Ph-H), 7.37 (s, 2H, Ph-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.24 (d, J = 11.3 Hz, 1H, Piperidinyl-H), 4.71 (d, J = 8.2 Hz, 2H, S-CH.sub.2-), 4.45 (d, J = 12.0 Hz, 1H, Piperidinyl-H), 3.98 (t, J = 6.2 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.16 (d, J = 14.0 Hz, 2H, Piperidinyl-H), 2.60 (t, J = 11.0 Hz, 1H, Piperidinyl-H), 2.42 (t, J = 7.0 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.07 (s, 3H, N-CH.sub.3), 1.73 (dt, J = 18.6, 9.1 Hz, 4H, -O-CH.sub.2CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.33 (d, J = 10.9 Hz, 2H, Piperidinyl-H). .sup.33C NMR (101 MHz, DMSO) δ 193.29, 172.68, 164.20, 160.74, 158.63, 153.14, 152.01, 147.01, 145.85, 140.47, 139.81, 130.75, 126.14, 123.94, 108.93, 106.28, 96.38, 93.54, 70.73, 60.68, 59.82, 56.55, 56.51, 50.57, 49.07, 37.35, 36.25, 28.52, 27.66, A.sub.8 .sup.1H NMR (400 MHz, DMSO) δ 8.60 (d, J = 2.0 Hz, 1H, Pyridyl-H), 8.45 (dd, J = 4.8, 1.5 Hz, 1H. Pyridyl-H), 7.79 (dt. J = 7.8, 1.8 Hz, 1H, Pyridyl-H), 7.36 (s, 2H, Ph-H), 7.34 (dd, J = 7.9, 4.8 Hz, 1H, Pyridyl-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.25 (d, J = 10.1 Hz, 1H, Piperidinyl-H), 4.56 (d, J = 5.0 Hz, 2H, -S-CH.sub.2-), 4.43 (d, J = 11.6 Hz, 1H, Piperidinyl-H), 3.98 (t, J = 6.1 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.20 (dt, J = 22.8, 11.9 Hz, 2H, Piperidinyl-H), 2.59 (t, J = 10.9 Hz, 1H, Piperidinyl-H), 2.42 (t, J = 6.8 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.06 (s, 3H, N-CH.sub.3), 1.78 - 1.65 (m, 4H, -O-CH.sub.2CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.34 (s,2H, Piperidinyl-H). .sup.13C NMR (101 MHz, DMSO) δ 193.57, 172.68, 164.20, 160.75, 158.63, 153.15, 152.00, 150.54, 148.83, 140.47, 139.84, 137.14, 133.25, 126.14, 123.93, 108.94, 106.32, 96.38, 93.56, 70.74, 60.68, 59.84, 56.57, 56.51, 50.59, 49.46, 38.22, 37.34, 28.54, 28.09. A.sub.9 .sup.1H NMR (400 MHz, DMSO) δ 8.43 (d, J = 2.3 Hz, 1H, Pyridyl-H), 7.86 (dd, J = 8.3, 2.5 Hz, 1H, Pyridyl-H), 7.47 (d, J = 8.2 Hz, 1H, Pyridyl-H), 7.36 (s, 2H, Ph-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.23 (d, J = 10.2 Hz, 1H, Piperidinyl-H), 4.57 (d, J = 4.4 Hz, 2H, -S-CH.sub.2-), 4.42 (d, J = 12.5 Hz, 1H, Piperidinyl-H), 3.98 (t, J = 6.1 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.85 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.21 (dt, J = 21.4, 11.8 Hz, 2H, Piperidinyl-H), 2.59 (t, J = 10.5 Hz, 1H, Piperidinyl-H), 2.42 (t, J = 6.6 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.06 (s, 3H, N-CH.sub.3), 1.77 - 1.64 (m, 4H, -O-CH.sub.2CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.32 (d, J = 10.3 Hz, 2H, Piperidinyl-H); .sup.13C NMR (101 MHz, DMSO) δ 193.26, 172.68, 164.20, 160.75, 158.63, 153.15, 152.01, 150.64, 149.41, 140.79, 140.47, 139.84, 133.28, 126.14, 124.46, 108.94, 106.32, 96.38, 93.56, 70.74, 60.68, 59.81, 56.57, 56.51, 55.39, 55.39, 50.58, 37.34, 37.12, 28.53, 27.87. A.sub.10 .sup.1H NMR (400 MHz, DMSO) δ 7.44 - 7.34 (m, 6H, Ph-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.27 (d, J = 11.2 Hz, 1H, Piperidinyl-H), 4.53 (d, J = 7.5 Hz, 2H, -S-CH.sub.2-), 4.43 (d, J = 12.6 Hz, 1H, Piperidinyl-H), 3.94 (t, J = 6.5 Hz, 2H, -O-CH.sub.2CH.sub.3CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H,Ph-OCH.sub.3), 3.84 is, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.33 - 3.23 (m, 1H, Piperidinyl-H), 3.22 - 3.14 (m, 1H, Piperidinyl-H), 2.65 (ddd, J = 13.9, 7.1, 3.2 Hz, 1H, Piperidinyl-H), 2.32 (t, J = 6.9 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2-N-), 2.07 (s, 3H, N-CH.sub.3), 1.73 (d, J = 11.4 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.68 - 1.58 (m, 2H, Piperidinyl-H), 1.44 (dd, J = 14.3, 7.2 Hz, 2H, Pipeperidinyl-H), 1.40 - 1.25 (m, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-); .sup.13C NMR (101 MHz, DMSO) δ 193.74, 172.69, 164.19, 160.73, 158.62, 153.12, 151.96, 140.45, 139.79, 136.28, 132.35, 131.46, 128.83, 126.13, 108.92, 106.17, 96.36, 93.54, 72.09, 60.65, 59.73, 56.54, 56.51, 52.99, 51.24, 49.45, 37.56, 28.15, 27.87, 24.00. A.sub.11 .sup.1H NMR (400 MHz, DMSO) δ 7.59 (dd, J = 6.7, 2.4 Hz, 1H, Ph-H), 7.51 - 7.46 (m, 1H, Ph-H), 7.39 (s, 2H, Ph-H), 7.36 - 7.29 (m, 2H, Ph-H), 6.85 (d, J - 1.7 Hz, 1H, Ph-H), 6.49 (d, J = 1.8 Hz, 1H, Ph-H), 5.36 (s, 1H, Piperidinyl-H), 4.60 (d, J = 6.5 Hz, 2H, -S-CH.sub.2-), 4.50 (s, 1H, Piperidinyl-H), 3.94 (t, J = 5.6 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.88 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.76 (s, 3H, Ph-OCH.sub.3), 3.21 (d, J = 11.0 Hz, 2H, Piperidinyl-H), 2.68 (s, 1H, Piperidinyl-H), 2.34 (d, J = 9.6 Hz, 3H, CH2, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.91 (s, 3H, N-CH.sub.3), 1.54 (dd, J = 42.6, 36.0 Hz, 6H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-, Piperidinyl-H), 1.34 - 1.15 (m, 1H, Piperidinyl-H), .sup.13C NMR (101 MHz, DMSO) δ 193.97, 172.71, 164.24, 164.24, 160.74, 158.63, 153.16,152.05, 140.35, 139.84, 134.09, 133.94, 130.03, 129.92, 127.88, 126.08, 108.90, 106.15, 96.41, 93.58, 71.70, 60.67, 6001, 56.57, 56.53, 52.74, 52.74, 37.10, 27.58, 27.57, 27.54, 21.57. A.sub.12 .sup.1H NMR (400 MHz, DMSO) δ 7.63 (dd, J= 12.3, 5.2 Hz, 2H, Ph-H), 7.43 - 7.37 (m, 3H, Ph-H), 6.84 (d, J - 2.1 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.25 (d, J = 11.5 Hz, 1H, Piperidinyl-H, 4.59 (d, J = 7.5 Hz, 2H, -S-CH.sub.2-), 4.42 (d, J = 12.5 Hz, 1H, Piperidinyl-H), 3.94 (t, J = 6.5 Hz, 2H, -O-CH-Ch.sub.3CH.sub.2CH.sub.2-N-), 3,90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3,84 (s, 3H, Ph-OCH.sub.2), 3.75 (s, 3H, Ph-OCH.sub.3), 3.19 (t, J = 11.6 Hz, 1H, Piperidinyl-H), 2.65 (t, J = 10.8 Hz, 1H, Piperidinyl-H), 2.32 (t, J = 6.9 Hz, 2-H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 2.07 (s, 3H, N-CH.sub.3), 1.74 (d, J = 11.5 Hz, 2H. -O-CH.sub.2-CH.sub.2-CH.sub.2CH.sub.2-N-), 1.62 (dd, J = 14.9,7.3 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.43 (dt, J = 14.4, 7.3 Hz, 2H, Piperidinyl-H), 1.33 (t, J = 11.2 Hz, 2H, Piperidinyl-H), 1.24 (t, J= 6.5 Hz, 1H, Piperidinyl-H): .sup.12C NMR (101 MHz, DMSO) δ 193.17, 172.70, 164.20, 160.73, 158.63, 153.13, 151.99, 140.45, 139.80, 134.87, 133.70, 133.51, 133.16, 129.35, 127.96, 126.13, 108.92, 106.19, 96.38, 93.56, 72.10, 60.66, S9.68, 56.55, 56.52, 52.98, 49.56, 38.71, 37.58, 27.86, 27.71, 24.00, A.sub.13 .sup.1H NMR (400 MHz, DMSO) δ 7.51 (td, J = 7.7, 1.6 Hz, 1H, Ph-H), 7.38 (s, 2H, Ph-H), 7.37 - 7.31 (m, 1H, Ph-H), 7.17 (ddd, J = 8.9, 8.4, 5.0 Hz, 2H, Ph-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J= 2.2Hz, 1H, Ph-H), 5.27 (d, J = 9.7 Hz, 1H, Piperidinyl-H), 4.52 (d, J = 4.3 Hz, 2H, -S-(CH.sub.2-), 4.42 (d, J = 11.1 Hz, 1H, Piperidinyl-H), 3,94 (t, J = 6.5 Hz, 2H, -O-CH.sub.2-CH.sub.2-CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.27 - 3.10 (m, 2H, Piperidinyl-H), 2.67 (t, J = 8.8 Hz, 1H, Piperidinyl-H), 2.34 (t, J = 6.7 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 2.08 (s, 3H, N-CH.sub.3), 1.74 (d, J = 11.5 Hz, 2H, -O-CH.sub.2CH.sub.2Ch.sub.2Ch.sub.2-N-), 1.68 - 1.59 (m, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.49- 1.40 (m, 2H, Piperidinyl-H), 1.33 - 1,21 (m, 2H, Piperidinyl-H). .sup.13C NMR (101 MHz, DMSO) δ 193.53, 172.69, 164.20, 162.15, 160.75, 159.71, 158.63, 153.14, 151.98, 140.45, 139.86, 132.00, 131.96, 130.25, 139.17, 126.13,124.98, 124.95, 123.65, 123.50, 115.93, 115.72, 108.95, 106.24, 96.37, 93.57, 72.09, 60.65, 59.73, 56.54, 56.50, 53.00, 49.44, 37.55, 34.92, 27.86, 23.98, 19.03, .sup.18F NMR (376 MHz.sub., DMSO) δ -116.85; A.sub.14 .sup.1H NMR (400 MHz.sub., DMSO) δ 7.38 (s, 2H, Ph-H), 7.22 - 7.15 (m, 3H, Ph-H), 7.09 - 7.05 (m, 1H, Ph-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6,48 (d, J = 2.2 Hz, 1H, Ph-H), 5.29 (d, J = 9.6 Hz, 1H, Piperidinyl-H), 4.50 - 4.34 (m, 3H, -S-CH.sub.2-, Piperidninyl-H), 3.94 (t, J = 6.4 Hz, 2H, -O-CH.sub.2-CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.20 (d, J = 19.5 Hz, 2H, Piperidinyl-H), 2.67 (s, 1H, Piperidinyl-H), 2.40-2.29 (m, 2H, -O-CH.sub.2CH.sub.2CH.sub.2Ch.sub.2-N-), 2.27 (s, 3H, Ph-CH.sub.3),2.09 (s, 2H, N-CH.sub.3), 1.75 (d, J = 11.2 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.68 - 1.59 (m, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.41 (d, J = 30.1 Hz, 4H, Piperindinyl-H). .sup.13C NMR (101 MHz.sub., DMSO) δ 194.20, 172.69, 164,20, 160.75, 158.62, 153.14, 151.98, 140.45, 139.86, 138.10, 136.51, 130.23, 128.84, 128.47, 126.77, 126.13, 108.95, 106.24, 96.37, 93,56, 72.07, 60.66, 59.80, 56.54, 56.50, 53.00, 49.07, 41.62, 37.54, 27.85, 23.99, 21.38, 19.03, A.sub.15 .sup.1H NMR (400 MHz, DMSO) δ 7.38 (s, 2H, Ph-H), 7.26 (d, J = 8.0 Hz, 2H, Ph-H), 7.12 (d, J = 7.8 Hz 2H, Ph-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.29 (d, J = 9.7 Hz, 1H, Piperidinyl-H), 4.45 (d, J = 3.9 Hz, 3H, -S-CH.sub.2-, Piperidinyl-H), 3.94 (t, J = 6.4 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.17 (s, 2H, Piperidinyl-H), 2.70 (s, 1H, Piperidinyl-H), 2.42 - 231 (m, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N), 2.27 (s, 3H, Ph-CH.sub.3), 2.11 (s, 3H, N-CH.sub.3), 1.75 (d, J = 11.6 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.68 - 1.59 (m, 2H, O-CH.sub.3CH.sub.2CH.sub.2CH.sub.2-N-), 1.42 (dd, J = 37.0, 6.8 Hz, 4H, Piperidinyl-H), .sup.13C NMR (101 MHz, DMSO) δ 194.28, 172.69, 164.21, 160.76, 158.63, 153.15, 151.99, 140.44, 139.86, 137.04, 133.51, 129.63, 129.58, 129.54, 129.49, 126.13, 108.94, 106.24, 96.38, 93.57, 72.05, 60.66, 59.81, 56.55, 56.51, 52.99, 49,07, 41.40, 37.51, 27.84, 23.87, 21.16, 19.03. A.sub.16 .sup.1H NMR (400 MHz, DMSO) δ 8.21 - 8.14 (m, 2H, Ph.H), 7.66 (d, J = 8.8 Hz, 2H, Ph-H), 7.38 (s, 2H, Ph-H), 6.83 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.25 (d, J = 8.7 Hz, 1H, Piperidninyl-H), 4.71 (d, J = 7.9 Hz, 2H, -S-CH.sub.2-), 4.46 (d, J = 10.7 Hz, 1H, Piperidinyl-H), 3.94 (t J = 6.4 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.3-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H Ph-OCH.sub.3), 3.25 - 3.15 (m, 2H, Piperidinyl-H), 2.69 (s, 1H, Piperidinyl-H), 2.36 (s, 2H, -O-CH.sub.2CH.sub.2Ch.sub.2CH.sub.2-N-), 2.10 (s, 3H, N-CH.sub.3), 1.77 (d, 1 = 11.0 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.63 (dd, J = 14.2, 6.7 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.50 - 1.34 (m, 4H, Piperidinyl-H). .sup.13C NMR (101 MHz, DMSO) δ 193.32, 172.69, 164.20, 160.75, 158.62, 153.14, 151.98, 147.02, 145.86, 140.45, 139.86, 130.74, 126.13, 123.92, 108.94, 106.23, 96.37, 93.56, 72.06, 60.66, 59.71, 56.55, 56.50, 53.00, 49.07, 37.54, 36.24, 28.12, 27.85, 23.92. A.sub.17 .sup.1H NMR (400 MHz, DMSO) δ 8.60 (d, J = 1.8 Hz, 1H, Pyridyl -H), 8.46 (dd, J = 4.7, 1.5 Hz, 1H, Pyridyl -H), 7.80 (d, J = 7.8 Hz, 1H, Pyridyl -H), 7.38 (s, 2H, Ph-H), 7.34 (dd, J = 7.8, 4.6 Hz, 1H, Pyridyl-H), 6.84 (d, J = 2.1 Hz, 1H, Ph-H), 6.49 (d, J = 2.1 Hz, 1H, Ph-H), 5.26 (d, J = 11.4 Hz, 1H, Piperidinyl-H), 4.58 - 4.55 (m, 2H, -5-CH.sub.2-), 4.44 (d, J = 13.1 Hz, 1H, Piperidinyl-H), 3.94 (t, J = 6.5 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H, Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.18 (dd, J = 15.1, 9.6 Hz, 2H, Piperidinyl-H), 2.65 (ddd, J = 11.0, 7.5, 3.7 Hz, 1H, Piperidinyl-H), 2.32 (t, J = 6.9 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 2.07 (s, 3H, N-CH.sub.3), 1.87 (s, 1H, Piperidinyl-H), 1.74 (d, J = 11.7 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.44 (dd, J = 14.1, 7.1 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.33 (d, J = 20.7 Hz, 2H, Piperidinyl-H), 1.28 - 1.17 (m, 1H, Piperidinyl-H). .sup.13C NMR (101 MHz, DMSO)δ 193.51, 172.69, 164.19, 160.73, 158.62, 153.13, 151.98, 150.54, 148.83, 140.45, 139.80, 137.15, 133.28, 126.13, 123.94, 108.92, 106.18, 96.37, 93.55, 72.10, 60.65, 59.70, 56.55, 56.51, 55.40, 53.00, 38.20, 37.57, 27.87, 27.70, 24.00. A.sub.18 .sup.1H NMR (400 MHz, DMSO) δ 8.44 (d, J = 2.3 Hz, 1H, Pyridyl-H), 7.87 (dd, J = 8.3, 2.5 Hz, 1H, Pyridyl -H), 7.47 (d, J = 8.2 Hz, 1H, Pyridyl -H), 7.39 (s, 2H, Ph-H), 6.84 (d, J = 2.2 Hz, 1H, Ph-H), 6.49 (d, J = 2.2 Hz, 1H, Ph-H), 5.24 (d, J = 11.6 Hz, 1H, Piperidinyl-H), 4.57 (d, J = 5.2 Hz, 2H, -S-CH.sub.2-), 4.43 (d, J = 11.9 Hz, 1H, Piperidinyl-H), 3.94 (t, J = 6.5 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 3.90 (s, 3H, Ph-OCH.sub.3), 3.87 (s, 6H, Ph-OCH.sub.3), 3.84 (s, 3H. Ph-OCH.sub.3), 3.75 (s, 3H, Ph-OCH.sub.3), 3.30 - 3.13 (m, 2H, Piperidinyl-H), 2.70 - 2.61 (m, 1H, Piperidinyl-H), 2.33 (t, J = 6.9 Hz, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 2.07 (s, 3H, N-CH.sub.3), 1.79 - 1.70 (m, 2H, -O-CH.sub.2CH.sub.2CH.sub.2CH.sub.2-N-), 1.68 - 1.57 (m, 2H, -O-CH.sub.3CH.sub.2CH.sub.2CH.sub.3-N-), L49 - 1.40 (m, 2H, Piperidinyl-H), 1.39 - 1.28 (m, 2H, Piperidinyl-H). .sup.12C NMR (101MHz, DMSO) δ 193.20, 172.69, 164.19, 160.73, 158.62, 153.13, 151.97, 150.63, 149.40, 140.80, 140.45, 139.80, 133.31, 126.13, 124.46, 108.92, 106.18, 96.37, 93.54, 72.09, 60.65, 59.67, 56.55, 56.52, 55.40, 52.95, 37.56, 37.10, 28.16, 27.87, 23.99.

[0139] Test for Inhibition of Cancer Cell Activity by Compound of Embodiment 19 (Taking Hepatocellular Carcinoma SMMC-7721 Cells as an embodiment):

Testing Method

(1) Cell Culture and Drug Effect

[0140] SMMC-7721 cells are cultured in DMEM high sugar medium containing 10% fetal bovine serum in a saturated humidity incubator at 37 °C and 5% CO2. The culture medium is changed every two days and passaged every 3-4 days. The drug is prepared as 1 mmol/L and 10 mmol/L storage solution using DMSO as solvent, when used, the concentration is diluted into 1 .Math.mol/L and 10 .Math.mol/Lwith culture medium, using DMSO as negative control group and gemcitabine as positive control group to act on cells in logarithmic growth phase.

(2) MTT Colorimetry

[0141] Cells in logarithmic growth phase are digested with 0.025% pancreatin, and then digested with DMEM high sugar medium containing 10% fetal bovine serum. After centrifugation, the cells are suspended in DMEM high sugar medium containing 10% fetal bovine serum. Take a 96-well plate and add 200.Math.L of sterile water seal to each hole around the plate to ensure saturated humidity in the experiment. In the middle six rows, 100 .Math.L of cell suspension are added respectively, and the cell concentration is about 3.5×104 cells /mL. The last row is blank control group, and the same volume of complete culture medium is added. In 37 °C, 5% CO2 saturated humidity incubator culture for 24 hours, cells completely adhere to the wall, remove the culture medium, add complete culture medium containing different drugs, 200.Math.L per hole. The blank control group is added with 200 .Math.L of complete culture medium, and the culture is continued. After 24 hours, the drug effect is observed and photographed under an inverted microscope. After 48 hours, the drug effect is also observed and photographed under an inverted microscope. Then the supernatant is removed. 100 .Math.L of 0.5 mg/mL MTT solution is added to each well. After 4 hours of continuous culture, purple crystal formazan is generated. 100 .Math.L of 10% SDS is added to each well. After 12 hours of culture in an incubator at 37°C, the OD value is measured with an enzyme reader at A571 wavelength. Repeat 6 wells for each sample concentration, and calculate the inhibition rate by taking the average value.

[00001]$\text{Inhibition rate}\left(\%\right)=\left(1-\frac{0\text{D value of drug treatment group}}{\text{Negative control group 0D value}}\right)\times 100\%$

Statistical Method

[0142] The experimental results are analyzed by SPSS11.5 and One-WayANOVA method, and P<0.05 showed that there are significant differences among the data.

[0143] 2. Test Results of Inhibition of Hepatocellular Carcinoma SMMC-7721 Cell Activity

TABLE-US-00003 in vitro inhibition rate of compound a prepared in Embodiments 1-18 on hepatoma SMMC-7721 cells for 48 hours at a set concentration Compound Inhibition Rate (%) Compound Inhibition Rate (%) 1 .Math.mol/L 10 .Math.mol/L 1 .Math.mol/L 10 .Math.mol/L A1 21.82 ± 2.34.sup.∗ 95.51 ± 4.16.sup.∗ A.sub.11 91.00 ± 2.86.sup.∗ 99.85±1.64.sup.∗ A.sub.2 25.44 ± 3.25.sup.∗ 96.13 ± 3.42.sup.∗ A.sub.12 98.09 ± 2.68.sup.∗ 99.28 ± 1.04.sup.∗ A.sub.3 18.16 ± 2.14.sup.∗ 97.35 ± 1.78.sup.∗ A.sub.13 46.96 ± 4.65.sup.∗ 99.76 ± 1.06.sup.∗ A.sub.4 20.66 ± 1.21.sup.∗ 99.85 ± 1.64.sup.∗ A.sub.14 96.65 ± 2.61.sup.∗ 100 ± 0.42.sup.∗ A.sub.5 12.32 ± 2.39.sup.∗ 97.52 ± 1.12.sup.∗ A.sub.15 16.38 ± 3.82.sup.∗ 99.52 ± 1.12.sup.∗ A.sub.6 34.32 ± 2.69.sup.∗ 98.12 ± 2.76.sup.∗ A.sub.16 26.84 ± 4.36.sup.∗ 99.85 ± 0.71.sup.∗ A.sub.7 27.70 ± 1.09.sup.∗ 99.35 ± 3.48.sup.∗ A.sub.17 68.42 ± 2.35.sup.∗ 100 ± 1.31.sup.∗ A.sub.8 15.48 ± 2.74.sup.∗ 99.85 ± 1.64.sup.∗ A.sub.18 33.58 ± 1.67.sup.∗ 100 ± 0.42.sup.∗ A.sub.9 18.83 ± 3.15.sup.∗ 99.76 ± 1.06.sup.∗ Gemcitabine 55.67 ± 2.26.sup.∗ 63.50 ± 2.18.sup.∗ A.sub.10 92.83 ± 3.84.sup.∗ 97.85 ± 3.35.sup.∗ Note: * the inhibitory rate of different drugs on SMMC-7721 cells at the set concentration is P < 0.05 compared with the negative control group

[0144] After preliminary tests, it is found that most of the compounds had no obvious inhibitory effect on SMMC-7721 cells at a concentration of 1 .Math.mol/L, but showed significant inhibitory effect on SMMC-7721 cells at a concentration of 10 .Math.mol/L, with the inhibitory rate exceeding 95%; The inhibition rate of some compounds to SMMC-7721 is over 90% at 1 .Math.mol/Lconcentration or 10 .Math.mol/L concentration, such as A10, A11, A12 and A14; The inhibitory activity is significantly higher than that of the positive control drug gemcitabine.

[0145] The above experimental activity data show that the dithiocarbamate-containing 4-(N-methyl) aminopiperidine myricetin derivative has a certain inhibitory effect on liver cancer SMMC-7721 cells, and some target compounds show excellent inhibitory activity on liver cancer SMMC-7721 cells, can be used as potential drugs for inhibiting liver cancer SMMC-7721 cells, and has a good application prospect.

[0146] As mentioned above, it is only a preferred embodiment of the present invention and is not intended to limit the present invention in any form. Any simple modifications, equivalent changes and modifications made to the above embodiments according to the technical essence of the present invention are still within the scope of the present invention.